What is Tirzepatide?

Tirzepatide (LY3298176) is a fatty-acid-modified 39-amino-acid peptide that activates the GIP and GLP-1 receptors. It is supplied here as a lyophilised powder for in-vitro laboratory research only.

Last editorial review: 2026-09-18 · Part of the Tirzepatide research hub

Definition and design

Tirzepatide is a single-chain synthetic peptide built on a GIP-based backbone and engineered to activate both the GIP and the GLP-1 receptor. Its earlier research designation is LY3298176, and it is commonly described in the literature as a dual incretin receptor agonist.

The design logic is that GIP and GLP-1 are the two principal incretin hormones, and that a single molecule engaging both receptors allows their combined contribution to be studied without co-administering two peptides that have different pharmacokinetic profiles.

Peptide chemistry

The 39-residue sequence carries non-natural amino acid substitutions that resist enzymatic cleavage, together with a C20 fatty di-acid side chain. As with other long-acting incretin analogues, that lipid chain drives reversible albumin binding, which is the structural feature responsible for the extended duration of action reported in the literature.

For laboratory handling the implications are the same as for other lipidated peptides: supplied freeze-dried, reconstituted in aqueous diluent, and sensitive to repeated freeze-thaw cycles, light and warmth.

Why it is a reference compound

Tirzepatide has the deepest evidence base of any dual incretin agonist, spanning receptor pharmacology, preclinical models and large phase 3 clinical programmes. That depth is why it functions as the comparator of choice when a newer molecule such as a tri-agonist is characterised.

In a research setting it therefore has two roles: a compound of interest in its own right, and a benchmark against which the incremental contribution of additional receptor activity can be assessed.

How it is supplied for research

Biovanta Research supplies tirzepatide as a lyophilised powder across eight vial strengths, each batch independently assayed by Janoshik Analytical with the certificate published before sale.

Material is supplied strictly for in-vitro laboratory research by qualified persons. It is not a medicine and is not for human or veterinary use, and no dosing guidance is provided.

Analytical verification

As with the other lipidated incretin peptides in this library, identity and purity are established through reversed-phase HPLC and mass spectrometry, run against the specific manufacturing batch rather than against the peptide in general. The certificate of analysis is the document that records those results and should be checked against the vial before any assay is designed around it.

Because tirzepatide’s fatty di-acid side chain increases hydrophobicity relative to the unmodified peptide backbone, HPLC methods for it are typically optimised with that in mind; a method validated for a different peptide class may not resolve tirzepatide-related impurities correctly.

Model systems and study design

Single-receptor recombinant cell lines with a cAMP reporter remain the standard first step for characterising tirzepatide’s activity at each receptor individually. Because the potency at GIP and GLP-1 receptors is not equal, experiments intended to detect bias or imbalance need matched assay conditions across both receptor lines, including equivalent expression levels where possible.

Beyond single-receptor systems, beta cell lines, adipocyte models and rodent studies are used to examine integrated responses; each introduces additional variables such as endogenous receptor expression and glucose sensitivity that must be reported alongside any result.

Regulatory status

Tirzepatide has a mature clinical record including phase 3 trials and, in some jurisdictions, marketing authorisation for specific indications outside the UK research-supply context described here. That authorisation status elsewhere does not change how it is supplied by Biovanta Research: material sold here is unlicensed research-grade peptide, supplied for in-vitro laboratory work only, with no dosing or human-use guidance provided.

Researchers should verify current UK and international regulatory status independently through the MHRA and equivalent bodies rather than relying on this summary, since regulatory status can change and differs by jurisdiction and by formulation.

Where tirzepatide sits in the incretin peptide class

Within the incretin peptide family, tirzepatide occupies the middle ground between single-receptor GLP-1 agonists such as semaglutide and triple-receptor agonists such as retatrutide. It was the first dual GIP/GLP-1 agonist to reach a large clinical evidence base, and that combination of dual-receptor design with an extensive published record is what makes it the standard reference point when a newer poly-agonist’s incremental receptor activity is being assessed.

Understanding where a given peptide sits on this single-to-dual-to-triple spectrum is useful context for interpreting any specific pharmacology result, since a finding attributed to tirzepatide’s GIP receptor activity, for example, is only informative if the comparator experiment correctly isolates that one variable.

Suitable model systems and experimental controls

Recombinant cell lines expressing a single human receptor, most commonly with a cAMP-based reporter, remain the standard starting point for characterising tirzepatide’s activity at the GIP and GLP-1 receptors independently. Because its potency at the two receptors is not equal, a well-controlled experiment states the relative expression level of each receptor construct and includes native GIP and native GLP-1 as reference agonists in every assay run, rather than relying on historical potency figures from a different plate or a different laboratory.

Beyond single-receptor systems, pancreatic beta cell lines are used for glucose-dependent insulin secretion assays, and rodent models of obesity or diabetes are used for integrated metabolic endpoints. Each of these systems introduces additional variables, such as endogenous receptor expression or diet composition, that should be reported alongside results so that findings can be compared fairly with other laboratories’ work.

Open questions and reading the primary literature

Several aspects of tirzepatide pharmacology remain active research questions, including the precise physiological weight of GIP receptor signalling relative to GLP-1 receptor signalling in different tissues, and how the reported biased signalling at the GLP-1 receptor translates into the integrated metabolic effects described in clinical studies. This summary should not be treated as a substitute for the primary literature on any of these points.

A standing PubMed search on tirzepatide, combined with periodic review of its ClinicalTrials.gov entries, is the most reliable way to track new pharmacology or clinical publications as they appear, since registry updates and journal publication schedules do not always move at the same pace.

Strength of the current evidence

Receptor pharmacology and clinical evidence for tirzepatide are both well developed and peer-reviewed. Material supplied here is research grade and unlicensed for any therapeutic purpose.

References

1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Molecular Metabolism, 2018 (PubMed)
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med, 2022 (DOI)
3. Indexed tirzepatide publications (PubMed search listing)

Related Tirzepatide research

• Mechanism of Action — How tirzepatide engages the GIP and GLP-1 receptors, and how signalling bias between them is characterised.

Back to the Tirzepatide research hub · Tirzepatide research material · Certificates of analysis

Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.